Annual CFF
$6.00 M
+$8.61 M+329.28%
December 31, 2023
Summary
- As of February 8, 2025, APVO annual cash flow from financing activities is $6.00 million, with the most recent change of +$8.61 million (+329.28%) on December 31, 2023.
- During the last 3 years, APVO annual CFF has fallen by -$17.88 million (-74.88%).
- APVO annual CFF is now -93.97% below its all-time high of $99.40 million, reached on December 31, 2014.
Performance
APVO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$4.91 M
+$940.00 K+23.68%
September 30, 2024
Summary
- As of February 8, 2025, APVO quarterly cash flow from financing activities is $4.91 million, with the most recent change of +$940.00 thousand (+23.68%) on September 30, 2024.
- Over the past year, APVO quarterly CFF has increased by +$1.86 million (+61.16%).
- APVO quarterly CFF is now -91.12% below its all-time high of $55.29 million, reached on September 30, 2016.
Performance
APVO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$11.92 M
+$565.00 K+4.98%
September 30, 2024
Summary
- As of February 8, 2025, APVO TTM cash flow from financing activities is $11.92 million, with the most recent change of +$565.00 thousand (+4.98%) on September 30, 2024.
- Over the past year, APVO TTM CFF has increased by +$5.92 million (+98.75%).
- APVO TTM CFF is now -87.78% below its all-time high of $97.55 million, reached on September 30, 2016.
Performance
APVO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
APVO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +329.3% | +61.2% | +98.8% |
| 3 y3 years | -74.9% | +61.2% | +98.8% |
| 5 y5 years | +862.1% | +3736.3% | -40.8% |
APVO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -77.1% | +329.3% | -18.2% | +199.4% | -54.4% | +183.9% |
| 5 y | 5-year | -77.1% | +329.3% | -80.2% | +122.2% | -84.8% | +153.4% |
| alltime | all time | -94.0% | +329.3% | -91.1% | +122.2% | -87.8% | +153.4% |
Aptevo Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $4.91 M(+23.7%) | $11.92 M(+5.0%) |
| Jun 2024 | - | $3.97 M(<-9900.0%) | $11.36 M(+44.3%) |
| Mar 2024 | - | -$3000.00(-100.1%) | $7.87 M(+31.2%) |
| Dec 2023 | $6.00 M(-329.3%) | $3.05 M(-29.9%) | $6.00 M(-33.0%) |
| Sep 2023 | - | $4.34 M(+803.1%) | $8.95 M(+118.0%) |
| Jun 2023 | - | $481.00 K(-125.7%) | $4.11 M(+818.6%) |
| Mar 2023 | - | -$1.87 M(-131.2%) | $447.00 K(-117.1%) |
| Dec 2022 | -$2.62 M(-110.0%) | $6.00 M(-1299.6%) | -$2.62 M(-77.6%) |
| Sep 2022 | - | -$500.00 K(-84.3%) | -$11.69 M(-17.7%) |
| Jun 2022 | - | -$3.18 M(-35.6%) | -$14.21 M(+423.0%) |
| Mar 2022 | - | -$4.94 M(+60.5%) | -$2.72 M(-110.4%) |
| Dec 2021 | $26.16 M(+9.6%) | -$3.08 M(+1.8%) | $26.16 M(-48.2%) |
| Sep 2021 | - | -$3.02 M(-136.3%) | $50.48 M(-35.5%) |
| Jun 2021 | - | $8.32 M(-65.3%) | $78.24 M(+11.9%) |
| Mar 2021 | - | $23.94 M(+12.7%) | $69.92 M(+192.9%) |
| Dec 2020 | $23.87 M(+18.5%) | $21.25 M(-14.1%) | $23.87 M(+858.4%) |
| Sep 2020 | - | $24.73 M(>+9900.0%) | $2.49 M(-111.2%) |
| Jun 2020 | - | $0.00(-100.0%) | -$22.21 M(-0.5%) |
| Mar 2020 | - | -$22.10 M(>+9900.0%) | -$22.33 M(-210.8%) |
| Dec 2019 | $20.15 M | -$135.00 K(-662.5%) | $20.15 M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | $24.00 K(-121.2%) | $20.32 M(+3.1%) |
| Jun 2019 | - | -$113.00 K(-100.6%) | $19.72 M(-2.1%) |
| Mar 2019 | - | $20.37 M(>+9900.0%) | $20.14 M(-2659.3%) |
| Dec 2018 | -$787.00 K(-104.0%) | $39.00 K(-106.7%) | -$787.00 K(+163.2%) |
| Sep 2018 | - | -$583.00 K(-286.3%) | -$299.00 K(-393.1%) |
| Jun 2018 | - | $313.00 K(-156.3%) | $102.00 K(-147.0%) |
| Mar 2018 | - | -$556.00 K(-205.5%) | -$217.00 K(-101.1%) |
| Dec 2017 | $19.53 M(-78.1%) | $527.00 K(-389.6%) | $19.53 M(-2.9%) |
| Sep 2017 | - | -$182.00 K(+2933.3%) | $20.11 M(-73.4%) |
| Jun 2017 | - | -$6000.00(-100.0%) | $75.58 M(-20.3%) |
| Mar 2017 | - | $19.20 M(+1635.5%) | $94.87 M(+6.2%) |
| Dec 2016 | $89.30 M(+74.0%) | $1.11 M(-98.0%) | $89.30 M(-8.5%) |
| Sep 2016 | - | $55.29 M(+186.7%) | $97.55 M(+89.5%) |
| Jun 2016 | - | $19.28 M(+41.6%) | $51.48 M(+1.8%) |
| Mar 2016 | - | $13.62 M(+45.5%) | $50.57 M(-1.5%) |
| Dec 2015 | $51.33 M(-48.4%) | $9.36 M(+1.5%) | $51.33 M(+22.3%) |
| Sep 2015 | - | $9.22 M(-49.8%) | $41.97 M(+28.1%) |
| Jun 2015 | - | $18.37 M(+27.7%) | $32.75 M(+127.7%) |
| Mar 2015 | - | $14.38 M | $14.38 M |
| Dec 2014 | $99.40 M(+89.6%) | - | - |
| Dec 2013 | $52.41 M | - | - |
FAQ
- What is Aptevo Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aptevo Therapeutics?
- What is Aptevo Therapeutics annual CFF year-on-year change?
- What is Aptevo Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aptevo Therapeutics?
- What is Aptevo Therapeutics quarterly CFF year-on-year change?
- What is Aptevo Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aptevo Therapeutics?
- What is Aptevo Therapeutics TTM CFF year-on-year change?
What is Aptevo Therapeutics annual cash flow from financing activities?
The current annual CFF of APVO is $6.00 M
What is the all time high annual CFF for Aptevo Therapeutics?
Aptevo Therapeutics all-time high annual cash flow from financing activities is $99.40 M
What is Aptevo Therapeutics annual CFF year-on-year change?
Over the past year, APVO annual cash flow from financing activities has changed by +$8.61 M (+329.28%)
What is Aptevo Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of APVO is $4.91 M
What is the all time high quarterly CFF for Aptevo Therapeutics?
Aptevo Therapeutics all-time high quarterly cash flow from financing activities is $55.29 M
What is Aptevo Therapeutics quarterly CFF year-on-year change?
Over the past year, APVO quarterly cash flow from financing activities has changed by +$1.86 M (+61.16%)
What is Aptevo Therapeutics TTM cash flow from financing activities?
The current TTM CFF of APVO is $11.92 M
What is the all time high TTM CFF for Aptevo Therapeutics?
Aptevo Therapeutics all-time high TTM cash flow from financing activities is $97.55 M
What is Aptevo Therapeutics TTM CFF year-on-year change?
Over the past year, APVO TTM cash flow from financing activities has changed by +$5.92 M (+98.75%)